These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27292159)

  • 21. Efficacy, effectiveness and safety of fumaric acid esters in the treatment of psoriasis: a systematic review of randomized and observational studies.
    Balak DM; Fallah Arani S; Hajdarbegovic E; Hagemans CA; Bramer WM; Thio HB; Neumann HA
    Br J Dermatol; 2016 Aug; 175(2):250-62. PubMed ID: 26919824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials.
    Langley RG; Reich K
    Br J Dermatol; 2013 Dec; 169(6):1198-206. PubMed ID: 23937204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
    Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada.
    Gupta AK; Daigle D; Lyons DC
    J Cutan Med Surg; 2014 Nov; 18(6):371-8. PubMed ID: 25348757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis.
    Wang J; Zhan Q; Zhang L
    Hum Vaccin Immunother; 2016; 12(2):431-7. PubMed ID: 26528924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM; Tung TH; Wang SH; Chi CC
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):355-362. PubMed ID: 29136293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy of biologics in psoriasis: a review.
    Kim IH; West CE; Kwatra SG; Feldman SR; O'Neill JL
    Am J Clin Dermatol; 2012 Dec; 13(6):365-74. PubMed ID: 22967166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
    Wong IT; Shojania K; Dutz J; Tsao NW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapies in psoriasis: a systematic review.
    Lee EB; Amin M; Bhutani T; Wu JJ
    Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
    Sorenson E; Koo J
    J Dermatolog Treat; 2015; 26(6):493-501. PubMed ID: 25886082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
    Alwawi EA; Krulig E; Gordon KB
    Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.